Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intensive chemotherapy + hematopoietic stem cell rescue-Institut Curie-primary central nervous system lymphoma
- Development stage
- Phase 2
- Lead developer
- ANOCEF-GOELAMS
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This treatment protocol is a consolidation therapy for primary central nervous system lymphoma (PCNSL) in patients aged 60 years and younger, evaluated in the PRECIS (ANOCEF-GOELAMS) randomized phase II trial. The protocol consists of intensive chemotherapy using the TBC regimen—a combination of high-dose thiotepa, busulfan, and cyclophosphamide—followed by autologous hematopoietic stem cell rescue (ASCT). This approach is typically administered after induction with methotrexate-based chemotherapy (such as R-MBVP) to achieve deep remission and eliminate residual lymphoma cells in the central nervous system while avoiding the long-term neurotoxicity associated with whole-brain radiotherapy (WBRT). The high-dose alkylating agents are selected for their ability to penetrate the blood-brain barrier, and the subsequent stem cell rescue is required to mitigate the severe myelosuppression caused by the intensive chemotherapy.
- Other names
- intensive chemotherapy + hematopoietic stem cell rescueTBC + ASCTthiotepa + busulfan + cyclophosphamide + autologous stem cell transplantationASCT consolidation
02
Targets
DNA
Beyond the preview
Go deeper on intensive chemotherapy + hematopoietic stem cell rescue-Institut Curie-primary central nervous system lymphoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intensive chemotherapy + hematopoietic stem cell rescue-Institut Curie-primary central nervous system lymphoma.